Universal Influenza A Vaccine in Healthy Adults

NCT05155319 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Influenza

Interventions

BIOLOGICAL: UFluA 20 µg each antigen/dose
BIOLOGICAL: UFluA 60 µg each antigen/dose
BIOLOGICAL: Placebo

Sponsor

Emergent BioSolutions